Abstract

The current epidemic of artemisinin resistant Plasmodium falciparum in Southeast Asia is the result of a soft selective sweep involving at least 20 independent kelch13 mutations. In a large global survey, we find that kelch13 mutations which cause resistance in Southeast Asia are present at low frequency in Africa. We show that African kelch13 mutations have originated locally, and that kelch13 shows a normal variation pattern relative to other genes in Africa, whereas in Southeast Asia there is a great excess of non-synonymous mutations, many of which cause radical amino-acid changes. Thus, kelch13 is not currently undergoing strong selection in Africa, despite a deep reservoir of variations that could potentially allow resistance to emerge rapidly. The practical implications are that public health surveillance for artemisinin resistance should not rely on kelch13 data alone, and interventions to prevent resistance must account for local evolutionary conditions, shown by genomic epidemiology to differ greatly between geographical regions.

https://doi.org/10.7554/eLife.08714.001

eLife digest

Malaria is an infectious disease caused by a microscopic parasite called Plasmodium, which is transferred between humans by mosquitos. One species of malaria parasite called Plasmodium falciparum can cause particularly severe and life-threatening forms of the disease. Currently, the most widely used treatment for P. falciparum infections is artemisinin combination therapy, a treatment that combines the drug artemisinin (or a closely related molecule) with another antimalarial drug. However, resistance to artemisinin has started to spread throughout Southeast Asia.

Artemisinin resistance is caused by mutations in a parasite gene called kelch13, and researchers have identified over 20 different mutations in P. falciparum that confer artemisinin resistance. The diversity of mutations involved, and the fact that the same mutation can arise independently in different locations, make it difficult to track the spread of resistance using conventional molecular marker approaches.

Here, Amato, Miotto et al. sequenced the entire genomes of more than 3,000 clinical samples of P. falciparum from Southeast Asia and Africa, collected as part of a global network of research groups called the MalariaGEN Plasmodium falciparum Community Project. Amato, Miotto et al. found that African parasites had independently acquired many of the same kelch13 mutations that are known to cause resistance to artemisinin in Southeast Asia. However the kelch13 mutations seen in Africa remained at low levels in the parasite population, and appeared to be under much less pressure for evolutionary selection than those found in Southeast Asia.

These findings demonstrate that the emergence and spread of resistance to antimalarial drugs does not depend solely on the mutational process, but also on other factors that influence whether the mutations will spread in the population. Understanding how this is affected by different patterns of drug treatments and other environmental conditions will be important in developing more effective strategies for combating malaria.

https://doi.org/10.7554/eLife.08714.002

Introduction

Artemisinin combination therapy (ACT), the frontline treatment for P. falciparum infection, has played a major part in reducing the number of deaths due to malaria over the past decade (World Health Organization, 2014b). However the increasing prevalence of artemisinin resistant P. falciparum across large parts of Southeast Asia threatens to destabilise malaria control worldwide (Dondorp et al., 2009; Hien et al., 2012; Phyo et al., 2012; Kyaw et al., 2013; Ashley et al., 2014; World Health Organization, 2014a). One of the main contemporary challenges in global health is to prevent artemisinin resistance from becoming established in Africa, where the consequences for childhood mortality could be disastrous (Dondorp and Ringwald, 2013).

Understanding the epidemiological and evolutionary driving forces behind artemisinin resistance is essential to develop effective strategies to stop it spreading. At the molecular level, artemisinin resistance is caused by mutations in a kelch protein encoded by PF3D7_1343700 on P. falciparum chromosome 13, referred to here as kelch13. More specifically, non-synonymous mutations in the kelch13 propeller and BTB-POZ domains (KPBD) result in reduced sensitivity of P. falciparum to artemisinin, as demonstrated by multiple lines of evidence including laboratory studies of artificially acquired resistance, genetic association studies of natural resistance and allelic replacement experiments (Ariey et al., 2014; Ghorbal et al., 2014; Miotto et al., 2015; Straimer et al., 2015; Takala-Harrison et al., 2015). Parasites with KBPD mutations tend to grow more slowly in the early part of the erythrocytic cycle, and have an enhanced unfolded protein response, both of which might act to protect against oxidative damage caused by artemisinin (Dogovski et al., 2015; Mok et al., 2015). It has also recently been shown that the PI3K protein is the target of artemisinin action, and that kelch13 binds to PI3K to mark it for degradation; by affecting this binding, KBPD mutations result in high levels of PI3K which counteract the effect of artemisinin (Mbengue et al., 2015).

A striking characteristic of the current distribution of artemisinin resistance is that it is caused by multiple independent KPBD mutations emerging in different locations, i.e. it does not originate from a single mutational event. More than 20 KPBD SNPs have been associated with delayed parasite clearance during artemisinin treatment and there are several documented instances of the same allele arising independently in different locations (Ashley et al., 2014; Miotto et al., 2015; Takala-Harrison et al., 2015). These are classic features of a soft selective sweep which, according to evolutionary theory, is most likely to arise in populations where the selected alleles are already present as standing genetic variations or have been repeatedly introduced by de novo mutations (Hermisson and Pennings, 2005; Pennings and Hermisson, 2006; Messer and Petrov, 2013). There is ongoing debate among evolutionary biologists about how commonly soft selective sweeps occur in nature (Jensen, 2014; Garud et al., 2015) but they have clearly played a role in previous forms of antimalarial drug resistance (Nair et al., 2007; Salgueiro et al., 2010) and the current epidemic of artemisinin resistance is the most extreme example of a soft selective sweep thus far observed in eukaryotes.

This creates a practical problem in monitoring the global spread of resistance. Artemisinin resistance can be measured directly, by following the rate of parasite clearance in patients (Flegg et al., 2011) or by testing parasite isolates in vitro (Witkowski et al., 2013), but these phenotypic assays are resource intensive and impractical for large-scale screening in resource-poor settings. Genetic approaches are therefore preferable for practical implementation of large-scale surveillance, but the soft selective sweep of artemisinin resistance produces much more heterogeneous genetic signatures than previous global waves of chloroquine and pyrimethamine resistance, where hard selective sweeps were the dominant mode of spread. Thus there is considerable uncertainty about the epidemiological significance of the growing number of non-synonymous KPBD mutations reported in Africa (Ashley et al., 2014; Hopkins Sibley, 2015; Kamau et al., 2015; Taylor et al., 2015). Previous studies in Africa have not identified variants known to cause resistance in Southeast Asia (Kamau et al., 2015; Taylor et al., 2015). At the same time, there are documented instances of African parasites that can be rapidly cleared by artemisinin treatment, although they carry KPBD mutations (Ashley et al., 2014). In the absence of comprehensive phenotypic data, it is not known which of these mutations, if any, are markers of resistance. This is a limitation of conventional molecular epidemiology, which tracks specific mutations and haplotypes and is poorly equipped to monitor soft selective sweeps where new mutations are continually arising on different haplotypic backgrounds, making it difficult to keep track of their phenotypic effects and evolutionary trajectories.

Here we explore how genomic data might help overcome these practical obstacles to monitoring the current epidemic of artemisinin resistance. This analysis includes genome sequencing data for 3,411 clinical samples of P. falciparum obtained from 43 locations in 23 countries. This large dataset was generated by the MalariaGEN Plasmodium falciparum Community Project, (www.malariagen.net/projects/parasite/pf), a collaborative study in which multiple research groups working on different scientific questions are sharing genome variation data to generate an integrated view of polymorphism in the global parasite population. Data resources arising from the present analysis, including genotype calls and sample metadata, can be obtained at www.malariagen.net/resource/16. The MalariaGEN Plasmodium falciparum Community Project also developed a user-friendly web application, with interactive tools for exploring and querying the latest version of the data: www.malariagen.net/apps/pf.

Results

Africa and Southeast Asia both have many kelch13 polymorphisms

Paired-end sequence reads were generated using the Illumina platform and aligned to the P. falciparum 3D7 reference genome, applying a series of quality control filters as previously described (see Materials and methods) (Manske et al., 2012; Miotto et al., 2013). The initial alignments identified 4,305,957 potential SNPs, which after quality control filtering produced a set of 935,601 exonic SNPs that could be genotyped with high confidence in the majority of samples, and that form the basis for the current analysis.

As summarised in Table 1, the dataset comprised 1,648 samples from Africa and 1,599 samples from Southeast Asia, allowing us to compare these two groups directly without the need for sample size corrections. We identified a total of 155 SNPs in the kelch13 gene, of which 128 were seen in Africa and 62 in Southeast Asia (Table 2). Studies in Southeast Asia have found that artemisinin resistance is associated with non-synonymous polymorphisms in the KPBD. Out of a total of 46 non-synonymous SNPs in these domains we found a similar number in Africa (n = 26) and Southeast Asia (n = 34), with 14 seen in both places (Table 3). Seven of those observed in Africa have previously been associated with artemisinin resistance in Southeast Asia, including C580Y, the most common allele in resistant parasites (Miotto et al., 2015).

Table 1

Count of samples analysed in this study.

https://doi.org/10.7554/eLife.08714.003
RegionCodeSample countsCountryCodeSample counts
West AfricaWAF957Burkina FasoBF56
CameroonCM134
GhanaGH478
Gambia, TheGM73
GuineaGN124
MaliML87
NigeriaNG5
East AfricaEAF412KenyaKE52
MadagascarMG18
MalawiMW262
TanzaniaTZ68
UgandaUG12
Central AfricaCAF279D. R. CongoCD279
South AmericaSAM27ColombiaCO16
PeruPE11
South AsiaSAS75BangladeshBD75
West Southeast AsiaWSEA497MyanmarMM111
ThailandTH386
East Southeast AsiaESEA1102CambodiaKH762
LaosLA120
VietnamVN220
OceaniaOCE62Indonesia (Papua)ID17
Papua New GuineaPG45
Table 2

Worldwide distribution of kelch13 mutations. Number of kelch13 propeller and BTB-POZ domain (KPBD) mutations present (not necessarily exclusively) in 5 populations (AFR = Africa, SEA = Southeast Asia, SAS = South Asia, OCE = Oceania, SAM = South America). Sample size is reported for each population.

https://doi.org/10.7554/eLife.08714.004
AFR
(N = 1,648)
SEA
(N = 1,599)
SAS
(N = 75)
OCE
(N = 62)
SAM
(N = 27)
Non-synonymousKPBD2634110
Upstream region4216211
SynonymousKPBD389100
Upstream region223100
Table 3

List of non-synonymous KPBD mutations. Non-synonymous mutations found in the kelch13 propeller and BTB-POZ domains (KPBD) and their position on chromosome Pf3D7_13_v3. For each mutation is reported where it has been observed and in how many samples. Where known, we reported if the mutation has been previously observed in patients with a prolonged parasite clearance half-life (>5 hr) by Miotto et al. 2014 and/or Ashley et al 2014. Sample size is reported for each population.

https://doi.org/10.7554/eLife.08714.005
MutationGenomic coordinatesAFR
(N = 1,648)
SEA
(N = 1,599)
SAS
(N = 75)
OCE
(N = 62)
SAM
(N = 27)
Observed in ART-R samples?
D353Y1725941-4---Yes
F395Y1725814-1---No
I416V172575211---
I416M17257501----
K438N1725684-1---No
P441L1725676-27---Yes
P443S1725671-1---
F446I1725662-7---Yes
G449A1725652-7---Yes
S459L172562222---
A481V1725556-4---Yes
S485N1725544-1---
Y493H1725521176---Yes
V520I17254401----
S522C172543421---Yes
P527H172541815---
C532S17254041----
V534L17253982----
N537I172538811---No
G538V1725385-19---Yes
R539T1725382-63---Yes
I543T1725370-34---Yes
P553L1725340224---Yes
A557S17253291----
R561H1725316124---Yes
V568G1725295-6---Yes
T573S17252802----
P574L1725277-12---Yes
R575K1725274-3---
A578S172526618----No
C580Y17252592423-1-Yes
D584V1725247-3---Yes
V589I17252332----
T593S17252211----
E612D17251621----
Q613E172516151---
Q613L17251601----No
F614L1725158-1---No
Y630F172510921---
V637I17250892----
P667A1724999-2---
P667L1724998-21--
F673I1724981-3---Yes
A675V1724974118---Yes
A676S172497223---
H719N172484318---Yes

kelch13 polymorphisms in Africa appear to be indigenous

We asked whether kelch13 polymorphisms seen in Africa had emerged independently, as opposed to migrating from Southeast Asia. We started by grouping samples according to genome-wide genetic similarity, based on a neighbour-joining (NJ) tree (Figure 1A). African and Southeast Asian samples formed two well-separated and distinct clusters, suggesting that gene flow between the two regions is very modest or negligible, a view supported by an alternative analysis using principal coordinate analysis (Figure 1B). None of the African parasites carrying kelch13 mutations grouped with the Southeast Asian population, supporting the idea that these mutations are indigenous.

Differentiation between African and Asian genomes.

(A) Neighbour-joining tree showing population structure across all sampling sites, with sample branches coloured according to country groupings (Table 1). Branches with large open tip circle indicate the sample is a kelch13 mutant, while those with a small black symbol are mixed infections (i.e. mixture of wild-type and mutant parasites or two mutant parasites with different mutations). Branches without tip symbols are kelch13 wild type. African kelch13 mutants are, at a genomic level, similar to other African samples. (B) Plot of second principal component (PC2) against the first (PC1), computed from a principal coordinate analysis (PCoA) of all samples in the present study, based on the same pairwise genetic distance matrix used for the tree of Figure 1A. PC1 clearly separates African samples from those collected in SEA, while PC2 is mainly driven by extreme population structure in ESEA.

https://doi.org/10.7554/eLife.08714.006

We considered that recombination between African and imported parasites could result in the transfer of DNA segments of Asian origin into genomes that otherwise appear to be local, and therefore not be easily detectable through genome-wide analysis. Thus, we analyzed the regions immediately flanking kelch13 in both directions, using a probabilistic method to reconstruct the most likely geographical origin of haplotypes observed in African kelch13 mutants (Figure 2). The vast majority of kelch13 mutants showed no evidence that flanking regions may have been imported, which indicates that most mutations observed in Africa do not have a common origin with those in Asia, and are likely to have emerged independently on a variety of haplotypes (Figure 2—figure supplement 1).

Figure 2 with 2 supplements see all
Local origin of African kelch13 mutations.

(A) Chromosome painting (see Materials and methods) of the 52 African kelch13 mutants across the two 250 kbp flanking regions on each side of the kelch13 gene. Each genome chunk is coloured according to the aggregated posterior probabilities that it originated in the African (red) or SEA (blue) population, according to the scale shown. (B) Detail of the flanking regions over a span of approximately 15 kbp, using the same colour scheme. The country of origin is indicated on the left, followed by the proportion of African chunks identified; the kelch13 mutation carried by the sample is shown on the right. Samples are sorted by the proportion of Asian chunks in this window, and the same order was applied to Panel A. Only five samples (lower region of the panel) show strong probability of Asian origin of the chunks closest to kelch13.

https://doi.org/10.7554/eLife.08714.007

Only 5 samples out of 56 were assigned a significant probability of Southeast Asian origin in at least one flanking sequence, and only two of these samples carried haplotypes similar to those in SEA mutants (Figure 2—figure supplement 2). Both in the NJ tree and in the PCA, these two African kelch13 mutants do not cluster with the bulk of African samples, but occupy a somewhat isolated position (Figure 1). We note that they exhibit unusually high levels of heterozygosity (FWS < 0.4), with mixed calls randomly distributed across the genome, consistent with a mix of African and SEA parasites. Continuous genetic monitoring of the parasite population will determine whether these are indeed just isolated cases, or they constitute very early evidence of gene flow between the two regions. Since these samples passed through a number of different laboratories, we cannot absolutely rule out the possibility that these mixtures could be the result of biological contamination during sample preparation and processing.

Across the genome there are many more rare variants in Africa

Historical demographic changes such as population expansions and bottlenecks (Tanabe et al., 2010), and epidemiological and environmental factors (Prugnolle et al., 2010) are highly influential forces that shaped the allele frequency spectra of P. falciparum populations across the globe (Nielsen et al., 2009; Manske et al., 2012). In order to properly contextualize the numbers and frequencies of kelch13 mutations, it is therefore important to characterize genomic variation patterns in different geographical regions.

One of the most striking features of this dataset is the high number of rare variations in the high-quality SNP list. At more than half of all polymorphic sites, the minor allele was only carried by a single sample (referred to as singletons, n = 330,783 or 35%) or by two samples (doubletons, n = 214,179 or 23%), often in heterozygous calls. By contrast, only 13,383 polymorphisms (1.4%) had a minor allele in ≥5% of samples. Rare alleles, however, are not evenly distributed geographically. There is a large excess of polymorphisms with minor allele frequency (MAF) below 0.1% in Africa (71% of all SNPs, vs. 17% in SEA), while numbers in the two regions are similar for SNPs with MAF>1% (2% of all SNPs, Figure 3a). Rare variations in Africa are not confined to a limited set of highly variable genes, but evenly distributed across the genome, as attested by the distribution of variants across all genes: SNP density in Africa (median = 67 SNPs/kbp, interquartile range = 51–84) is approximately 3.9 times higher than in SEA (median = 17, IQR = 13–22, p < 10–16, Figure 3b). Very similar ratios are estimated in both non-synonymous (Africa median SNP density = 43, IQR = 27–58; SEA median = 11, IQR = 7–15) and synonymous variants (Africa median SNP density=25, IQR = 20–30, SEA median = 6, IQR = 4–8). Accordingly, we found virtually identical distributions of the ratio of non-synonymous to synonymous mutations (N/S ratio) in the two regions (Figure 3c). This suggests that the huge disparity in SNP density between the two regions is more likely to be the result of different demographic histories and epidemiological characteristics, such as changes in effective population size (Joy et al., 2003), rather than the product of different selective constraints.

Figure 3 with 1 supplement see all
Number and density of variants in Africa and Southeast Asia.

(a) Allele frequency spectrum for Africa (red) and SEA (blue). Polymorphisms were binned by their minor allele frequency (MAF), and the counts in each bin were plotted against frequency, shown on a logarithmic scale. Although the number of high-frequency variations is consistent between the two regions, samples from Africa possess an excess of low-frequency variations. (b) SNP density per gene: for each gene, the number of variants found in the two regions is normalized by the length of the coding region (in kbp). African samples have on average 3.9 times more mutations than parasites from SEA. (c) Non-synonymous/synonymous ratio per gene: ratios of non-synonymous to synonymous mutations found per gene are similar in the two regions. To reduce artifacts due to small numbers, only genes with at least 10 SNP were considered in both analyses.

https://doi.org/10.7554/eLife.08714.010

In summary, we observe many more rare variants in Africa than in SEA; however we expect N/S ratios to be similar in these two regions in genes that are not subjected to selective pressures.

Comparing kelch13 with other parts of the genome

The density of kelch13 synonymous variations in the two continents is roughly consistent with that observed in the rest of the genome (Africa: 28 SNPs/kbp, SEA: 6; Figure 4a), which is expected since synonymous changes are less likely to be affected by selection. The excess of African non-synonymous mutations in the upstream region is also consistent with expectations (Africa: 44 SNPs/kbp, SEA: 16). In contrast, non-synonymous polymorphisms in the KPBD show a reversal of this relationship: SEA parasites possess about 30% more polymorphisms than African ones (34 in SEA vs. 26 in AFR). In addition, all but two non-synonymous changes in the KPBD are observed in Africa at very low frequency (singletons and doubletons), while in SEA more than half of the changes are observed in >2 samples (Table 4 and Figure 3—figure supplement 1).

Structure of kelch13, positioning of mutations in Africa and Southeast Asia, and sequence conservation.

(a) The amino acid positions of kelch13 polymorphisms observed in Africa (red) and SEA (blue) are shown. Coloured rectangles describe the extents of the resistance domains (BTB/POZ: aa. 349–448; kelch propeller: aa. 443–721) and upstream region, with the locations of non-synonymous changes indicated above, and that of synonymous changes below. Short lines represent singleton/doubleton mutations, while longer lines represent more frequent mutations. (b) Conservation score across amino acid residues of kelch13, derived by applying a CCF53P62 matrix on alignments of the P. falciparum gene coding sequence with its homologues in six other Plasmodium species for which high-quality sequence data were available: P. reichenowi, P. vivax, P. knowlesi, P. yoelii, P. berghei, and P. chabaudi (see Materials and methods). Although the region below position 200 is less conserved, particularly in rodent species (P. yoelii, berghei, and chabaudi), there is remarkably high conservation across all species over the rest of the gene, which includes the KPBD.

https://doi.org/10.7554/eLife.08714.012
Table 4

Frequency of the non-synonymous KPBD mutations. Counts of non-synonymous mutations in the conserved propeller and BTB-POZ domains of kelch13 are shown for each geographical region, stratified by the number of samples in which they are observed. Sample size for each population is reported.

https://doi.org/10.7554/eLife.08714.013
AFR
(N = 1,648)
SEA
(N = 1,599)
SAS
(N = 75)
OCE
(N = 62)
SAM
(N = 27)
1–2 samples2413110
3–5 samples17000
>5 samples114000

At a first approximation, these observations are consistent with a high number of non-synonymous changes that have risen in frequency in SEA parasites because of their association with artemisinin resistance, and a low number of mostly rare alleles in Africa, where artemisinin has been introduced more recently and resistance is yet to be reported.

Comparing kelch13 to other highly conserved genes

Although the function of kelch13 is as yet unclear, an alignment of its homologous gene sequences in eight Plasmodium species shows that the propeller and BTB-POZ domains are part of a highly conserved region (Figure 4b), suggesting a crucial role in parasite fitness. A reconstruction of ancestral alleles from this alignment suggests that P. falciparum accumulated only five conservative amino acid changes in the kelch13 propeller domain since diverging from other species 55 Myr ago (Escalante and Ayala, 1995) (Table 5). Given this extreme level of conservation, non-synonymous polymorphisms may appear surprisingly numerous in the present dataset, both in SEA (n = 34) and in Africa (n = 26). Such elevated numbers may be produced by selection processes; alternatively, they may be present in a large neutrally-evolving population, in which low-frequency variations continually emerge, but can only be detected for a brief span of time before they are removed by genetic drift and/or purifying selection. The question is, then, whether neutral evolution can account for the pattern of kelch13 mutations observed here.

Table 5

Kelch13 propeller domain mutations in different Plasmodium species. Here we report amino acid allele differences in a multiple sequence alignments of kelch13 homologues for seven species of Plasmodium parasites for which high-quality sequence data were available: P. falciparum (Pf), P. reichenowi (Pr), P. vivax (Pv), P. knowlesi (Pk), P. yoelii (Py), P. berghei (Pb), and P. chabaudi (Pc). The species formed three groups by similarity: Laverania (Pf, Pr), primate Plasmodia (Pv, Pk) and rodent Plasmodia (Py, Pb and Pc). An allele shared by all members of two different groups was identified as a putative ancestral allele. The table shows, for each position where at least one species exhibits a difference from the others: the amino acid position in the Pf kelch13 sequence; the putative ancestral amino acid allele; the alleles in the various species (columns with heading listing multiple species show mutations common to those species); and a substitution score of the mutation, based on a CCF53P62 substitution matrix (see Materials and methods). All substitution scores are ≥0, denoting conservative substitutions.

https://doi.org/10.7554/eLife.08714.014
Pf PositionAncestral AllelePf,PrPv,PkPkPy,Pb,PcPy,PbPbPcSubstitution Score
434F------Y2
447C----S--1
448I-M-----2
517TV------0
519FY------2
520V---L---0
534V---I---2
550S--C----1
566V---I---2
568V-I-----2
578A-S-----0
584D--E----1
590I----V--2
593T---A---0
605DE------1
613Q----N-K0
648D---E---1
666V---I---2
676A---T---0
691DE------1
708IL------0
711S-----P-0
723I---V---2

To answer this question, we compared patterns of kelch13 mutations to those in the rest of the P. falciparum genome Supplementary file 1 . Since fewer non-synonymous mutations are expected in more conserved genes, we applied genomic calibration, i.e. we stratified these analyses by evolutionary conservation. Each gene was assigned a conservation score determined from a sequence alignment of the P. falciparum gene with its P. chabaudi homologue, using a substitution matrix corrected for the AT bias in the Pf genome (Brick and Pizzi, 2008). P. chabaudi was chosen since it was the member of the group most differentiated from P. falciparum (rodent plasmodia) with the most complete reference sequence. A genome-wide non-linear negative correlation between gene conservation and N/S ratio is clearly observable; this trend is almost identical in the two populations (Figure 5a). Although kelch13 did not diverge significantly from this relationship in Africa (P = 0.2), its N/S ratio in SEA was the highest observed at its level of conservation, far exceeding the expected ratio (P<0.001). Accordingly, kelch13 showed the most significant difference in N/S ratios between Africa and SEA genome-wide (3.7-fold, P = 2 × 10-4 by Fisher’s exact test, Figure 5b and Supplementary file 1), even compared to other well-known drug resistance genes (Figure 5—figure supplement 1). Such unusually high N/S ratio in SEA parasites is mainly due to an excess of high frequency non-synonymous variations (Figure 5—figure supplement 2), suggesting that multiple independent origins of artemisinin resistance (Miotto et al., 2015; Takala-Harrison et al., 2015) have produced an unusually large number of common non-synonymous mutations.

Figure 5 with 2 supplements see all
Genome-wide analysis of N/S ratio.

(a) For each gene with more than 2 synonymous or non-synonymous SNPs, the N/S ratio in Africa (red points) and in SEA (blue points) are plotted against the conservation score of the gene coding sequence. The kelch13 gene values are represented by larger circles. For each region, a solid line show median values, while dotted lines delimit 95% of the genes at varying levels of conservation. This plot is truncated on the y-axis to show more clearly the bulk of the distribution; the full range is shown in Figure 5—figure supplement 2. (b) Histogram showing the distribution of the ratio of N/S ratios in SEA and Africa, for all genes with ≥5 synonymous and ≥5 non-synonymous SNPs on each region. An arrow shows the placement of kelch13.

https://doi.org/10.7554/eLife.08714.015

From this analysis we conclude that the high prevalence of kelch13 non-synonymous variants in SEA is not explainable by neutral evolution, but is consistent with selection of artemisinin-resistance alleles. In Africa, on the other hand, the observed non-synonymous changes appear to constitute a “physiological” level of variation consistent with a population rich in low-frequency alleles.

In Southeast Asia there are more radical substitutions in kelch13

The different kelch13 mutation repertoires in Africa and in SEA raise the question of whether these sets of mutations have different structural and functional properties. While there is high conservation across the whole of the propeller domain, it is unlikely that all possible amino acid changes have the same functional relevance or that they all carry the same fitness cost for parasites. Although direct measures of functional relevance are not yet available, and the exact function of kelch13 is hitherto unknown, we can make statistical comparisons of some properties of the observed changes, in at least two respects. First, assuming that kelch13 function is conserved across Plasmodium species, we can assess the strength of evolutionary constraints at any given position by examining whether amino acid substitutions between species are conservative or radical. Second, given that kelch proteins have been shown in other organisms to play an adapter role, with key binding sites defined by the arrangement of hydrophobic β-strands in the propeller domain (Adams et al., 2000), we can assess changes in hydrophobicity caused by the observed mutations, which may be informative of their functional importance.

Detailed mapping against the secondary structure of the propeller domain suggests that the polymorphisms found in SEA parasites occur in different blades, preferentially at positions proximal to the first and second β-strand of the propeller’s blades (Figure 6). This may indicate that these two strands play a role in defining the binding interface to the PI3K protein involved in artemisinin resistance (Mbengue et al., 2015), but this needs to be confirmed by in-depth structural analyses.

Figure 6 with 1 supplement see all
Structure of the kelch13 propeller domain, showing the position of mutations in Southeast Asia and Africa.

The sequence of the kelch13 propeller domain (amino acids 443–726) is organized according to its 6-blade tertiary structure, with the four β-strands characterizing each blade highlighted in colour. Polymorphisms observed in SEA (top panel) and Africa (bottom panel) are shown by circles above the mutated position. Small circles indicate very rare mutations (singletons and doubletons), while larger circles are used for more frequent mutations.

https://doi.org/10.7554/eLife.08714.018

We characterized changes in the propeller domain by a conservation score derived from a substitution matrix specific to AT-rich genomes (Brick and Pizzi, 2008), and assigned a hydrophobicity score to each site, estimated from the Kyte-Doolittle (KD) hydropathicity score (Kyte and Doolittle, 1982). The five putative derived alleles that have become established in the P. falciparum kelch13 propeller domain since its divergence from other Plasmodia are all conservative changes at hydrophilic sites (Figure 6—figure supplement 1a). Common mutations in Africa have characteristics broadly consistent with this conservative history of change (Figure 6—figure supplement 1b and Table 6). Polymorphisms in SEA parasites, on the other hand, show a pattern of changes that are more radical than those in Africa (P = 10–3) and more commonly found at hydrophobic sites (Figure 6—figure supplement 1c and Table 6).

Table 6

Conservation score of KPBD mutations.The table shows, for each non-synonymous KPBD mutation observed in the dataset, the number of samples carrying the mutation in Africa (AFR), in Southeast Asia (SEA), and a substitution score of the mutation, based on a CCF53P62 substitution matrix; lower values indicate more radical substitutions. Mutations observed in Africa tend to have higher conservation score, whereas in SEA mutations tend to be more radical.

https://doi.org/10.7554/eLife.08714.020
MutationAFRSEACFF53P62
Q613E

5

1

2

Y630F212
V637I202
V589I202
T573S202
Y493H1762
I416V112
T593S102
V520I102
I416M102
F395Y012
S522C211
E612D101
C532S101
R575K031
A578S1800
A676S230
V534L200
R561H1240
A675V1180
H719N180
P527H150
A557S100
R539T0630
I543T0340
G449A070
F446I070
A481V040
F673I030
P667A020
F614L010
S485N010
P443S010
C580Y2423-2
D353Y04-2
K438N01-2
P553L224-3
P441L027-3
G538V019-3
P574L012-3
V568G06-3
P667L02-3
S459L22-4
N537I11-4
Q613L10-4
D584V03-5

Taken together, the above results suggest that the propeller domain has long been under very strong evolutionary constraints, and that the number and nature of the changes observed in African parasites is consistent with these constraints, once we discard the abundant rare alleles expected in such a large population. In contrast, mutations in SEA parasites are not only far more numerous than expected, but they produce radical changes that are likely to be important determinants of the binding properties of the kelch13 protein, consistent with recent findings that binding of kelch13 to the PI3K protein is a critical factor in P. falciparum response to artemisinin (Mbengue et al., 2015).

Genetic background

A recent study has shown that resistance-causing KPBD mutations are significantly more likely to arise in parasites with a particular genetic background (Miotto et al., 2015). This predisposing genetic background is marked by specific SNP alleles of the genes encoding ferredoxin (fd), apicoplast ribosomal protein S10 (arps10), multidrug resistance protein 2 (mdr2) and chloroquine resistance transporter (crt). Here we extend this analysis, confirming that this particular combination of variants is extremely common in the parts of Southeast Asia where artemisinin resistance is known to be established, and is absent from Africa and other regions sampled here (Table 7).

Table 7

Frequency of the genetic background alleles across the world. Frequency of the four genetic background alleles identified in Miotto et al. (2015) for each geographical region. For each SNP, we show mutation name; chromosome number; nucleotide position; and frequencies of the mutant allele in the various populations.

https://doi.org/10.7554/eLife.08714.021
MutationChrPosAFRSASSEAPNGSAM
arps10-V127M1424810700.0%0.0%59.4%0.0%0.0%
fd-D193Y137483950.1%2.2%62.8%23.9%0.0%
mdr2-T484I1419562250.1%5.7%64.2%0.4%0.0%
crt-N326S74053620.8%28.2%68.6%0.1%0.0%

Discussion

This study demonstrates the value of genomic data in characterising the current epidemic of artemisinin resistance, which is problematic for conventional molecular epidemiology since new resistance-causing mutations are continually emerging on different haplotypic backgrounds. A key problem is to define the geographical origin of KBPD mutations, and we show that this can be solved by using genomic epidemiological data to analyse ancestral relationships between samples, thereby demonstrating that the KPBD mutations observed in Africa are of local origin.

Another important question is whether KPBD mutations are under positive selection in Africa, which is difficult to determine by standard haplotype-based methods because so many independent mutations are involved. This question is further complicated by marked geographical variation in normal levels of genetic diversity, i.e. there are many more rare variants in Africa than Southeast Asia, most likely due to the larger population size and other demographic factors (Manske et al., 2012). Here we address this question by comparing kelch13 against other genes in the same samples, a process that we refer to as genomic calibration. We show that for most genes the ratio of non-synonymous to synonymous mutations is relatively constant across geographical regions, despite geographic differences in genetic diversity, and that this ratio is correlated with the level of sequence conservation across different Plasmodium species. When calibrated against other genes with the same level of cross-species conservation, allowing for geographical differences in the overall level of genetic diversity, kelch13 shows a marked excess of non-synonymous substitutions in Southeast Asia, but appears normal in Africa. Moreover, KPBD mutations causing radical amino acid changes at highly conserved positions are found at relatively high frequency in Southeast Asia but remain at very low frequency in Africa. Taken together, these findings indicate that non-synonymous KBPD mutations are undergoing strong evolutionary selection in Southeast Asia, whereas those seen in Africa have originated locally and most likely reflect normal variation.

These findings have practical implications for the prevention of artemisinin resistance in Africa, where there is evidently a deep reservoir of low frequency genetic variations that could potentially allow resistance to emerge rapidly as the levels of selective pressure increase. In most parts of Africa, the selective pressure of artemisinin is probably relatively low at present, for several reasons. Artemisinin has been widely used in Southeast Asia for over two decades, whereas its usage in Africa is more recent, and it is estimated that only 20% of infected African children currently have access to frontline treatment ACT medication (World Health Organization, 2014b). Another factor is that people living in regions of high malaria endemicity acquire partial immunity, resulting in asymptomatic infection, so that there is a large reservoir of parasites in Africa that are not exposed to antimalarial drugs because asymptomatic individuals do not seek treatment (Hastings, 2003). The situation could change dramatically as malaria control efforts are intensified, and it will be vital to monitor the effects of major interventions on the emergence of resistance, particularly in African countries that have already achieved relatively low levels of malaria transmission. A key question for the future is whether parasite populations in certain locations possess genetic features that predispose to the emergence of artemisinin resistance, as suggested by the strong association of certain fd, arps10, mdr2 and crt alleles with resistance-causing KPBD mutations in Southeast Asia (Miotto et al., 2015). Another concern is that growing resistance to ACT partner drugs, now emerging in Southeast Asia (Saunders et al., 2014) may spread to Africa, or evolve independently there, and lead to increased selective pressure for artemisinin resistance there.

The global spread of resistance to chloroquine and sulfadoxine-pyrimethamine was dominated by hard sweeps of specific haplotypes originating in Southeast Asia, although it is clear that there were also localised emergences (Mita et al., 2009). Although we still know relatively little about the functional properties of different KPBD mutations, it is clear that some are more successful than others, e.g. the C580Y allele has emerged at multiple locations in Southeast Asia and Africa, and a specific C580Y haplotype is approaching fixation in large parts of Western Cambodia (Miotto et al., 2015). The high level of sequence conservation of KPBD across Plasmodium species indicates that mutations in these domains incur fitness costs, and this is supported by the observation that although there have been multiple independent origins of resistance-causing kelch13 mutations, individual kelch13 mutations appear to have limited spread, implying that there is a substantial fitness cost in the absence of sustained drug pressure. The danger is that these fitness costs may be compensated by other genetic variants, either in kelch13 or elsewhere in the genome, and that, as a result of this continuing evolutionary process, parasites in Southeast Asia will progressively acquire higher levels of artemisinin resistance (World Health Organization, 2014a) coupled with strong biological fitness and the ability to propagate across a wide range of vector species. Under these circumstances, the current soft sweep of artemisinin resistance could give way to a pervasive hard sweep with potentially disastrous consequences.

These findings demonstrate the utility of applying genomic epidemiology to identify features of parasite demography and evolution that affect how drug resistance spreads. Future strategies to combat resistance will require better understanding of the evolutionary consequences of malaria control interventions, e.g. how the selective advantage of a resistance allele is counterbalanced by its fitness cost under different control regimes and in different geographical settings. It is now possible to approach this problem prospectively, by conducting systematic spatiotemporal sampling and genome sequencing of the parasite population as an integral part of public health interventions to prevent resistance spreading.

Materials and methods

Ethical approval

Request a detailed protocol

All samples in this study were derived from blood samples obtained from patients with P. falciparum malaria, collected with informed consent from the patient or a parent or guardian. At each location, sample collection was approved by the appropriate local and institutional ethics committees. The following local and institutional committees that gave ethical approval for the partner studies: Comité d'Éthique, Ministère de la Santé, Bobo-Dioulasso, Burkina Faso; Navrongo Health Research Centre Institutional Review Board, Navrongo, Ghana; Kintampo Health Research Centre Institutional Ethics Committee, Kintampo, Ghana; Noguchi Memorial Institute for Medical Research Institutional Review Committee, University of Ghana, Legon, Ghana; Ghana Health Service Ethical Review Committee, Accra, Ghana; Gambia Government/MRC Joint Ethics Committee, Banjul, The Gambia; Comité d'Ethique National Pour la Recherche en Santé, Guinea; Ethics Committee of Faculté de Médecine, de Pharmacie et d'Odonto-Stomatologie, University of Bamako, Bamako, Mali; Ethical Review Committee, University of Ilorin Teaching Hospital, Ilorin, Nigeria; Institutional Review Board, Faculty of Health Sciences, University of Buea, Cameroon; Comité d’Ethique, Ecole de Santé Publique, Université de Kinshasa, Ministère de l’Enseignement Superieur, Universitaire et Recherche Scientifique, D. R. Congo; Comité National d'Ethique auprès du Ministère de la Santé Publique, Madagascar; Institutional Review Committee, Med Biotech Laboratories, Kampala, Uganda and Uganda National Council for Sciences and Technology (UNCST); College of Medicine Research Ethics Committee, University of Malawi, Blantyre, Malawi; KEMRI National Ethical Review Committee, Kenya; Medical Research Coordinating Committee of the National Institute for Medical Research, Tanzania; Ethical Review Committee, Bangladesh Medical Research Council, Bangladesh; Ethics Committee of the International Centre for Diarrheal Disease Research, Bangladesh; Institutional Ethical Review Committee, Department of Medical Research (Lower Myanmar); Ministry of Health, Government of The Republic of the Union of Myanmar; National Ethics Committee for Health Research, Ministry of Health, Phnom Penh, Cambodia; Ministry of Health National Ethics Committee For Health Research, Laos; Ethics Committee, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Ethical Committee, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam; Eijkman Institute Research Ethics Commission, Jakarta, Indonesia; Institutional Review Board, Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea; Institutional Review Board, International Center for Medical Research and Training, Cali, Colombia; Institutional Review Board, Universidad Nacional de la Amazonia Peruana, Iquitos, Peru; Human Research Ethics Committee of NT Department of Health and Families and Menzies School of Health Research, Darwin, Australia; Institutional Review Board, New York University Medical School, NY, USA; Institutional Review Board, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA; Institutional Review Board, Walter Reed Army Institute of Research, Washington DC, USA; Ethics Review Committee, World Health Organization, Geneva, Switzerland; Ethics Committee of the Faculty of Medicine, Heidelberg, Germany; Ethics Committee of the Medical University of Vienna; Ethics Committee, London School of Hygiene and Tropical Medicine, London, UK; Oxford Tropical Research Ethics Committee, Oxford, UK.

Sample preparation, sequencing and genotyping

Request a detailed protocol

DNA was extracted directly from blood samples taken from patients at admission time, after leukocyte depletion to minimize human DNA. Leukocyte depletion was achieved by CF11 filtration in most samples (Venkatesan et al., 2012), or alternatively by Lymphoprep density gradient centrifugation (Axis‐Shield, Dundee, UK) followed by Plasmodipur filtration (Euro‐Diagnostica, Malmö, Sweden) (Auburn et al., 2011) or by Plasmodipur filtration alone. Genomic DNA was extracted using the QIAamp DNA Blood Midi or Maxi Kit (Qiagen, Hilden, Germany), and quantities of human and Plasmodium DNA were determined by fluorescence analysis using a Qubit instrument (Invitrogen, Carlsbad, California) and multi-species quantitative PCR (Q‐PCR) using the Roche Lightcycler 480 II system, as described previously (Manske et al., 2012). Samples with >50 ng DNA and <80% human DNA contamination were selected for sequencing on the Illumina HiSeq platform following the manufacturer’s standard protocols (Bentley et al., 2008). Paired‐end sequencing reads of length 200–300 bp were obtained, generating approximately 1 Gbp of read data per sample. All short read sequence data have been deposited in the European Nucleotide Archive (http://www.ebi.ac.uk/ena/data/search/?query=plasmodium), and metadata will be released at the time of publication.

Polymorphism discovery, quality control and sample genotyping followed a process described elsewhere (Manske et al., 2012). Short sequence reads from 3,411 P. falciparum samples included in the MalariaGEN Plasmodium falciparum Community Project (http://www.malariagen.net/projects/parasite/pf) were aligned against the P. falciparum 3D7 reference sequence V3 (ftp://ftp.sanger.ac.uk/pub/pathogens/Plasmodium/falciparum/3D7/3D7.latest_version/version3/), using the bwa program (Li and Durbin, 2009) (http://bio-bwa.sourceforge.net/) as previously described (Manske et al., 2012), to identify an initial global set of 4,305,957 potential SNPs. This list was then used to guide stringent re-alignment using the SNP-o-matic algorithm (Manske and Kwiatkowski, 2009), to reduce misalignment errors. The stringent alignments were then examined by a series of quality filters, with the aim of removing alignment artefacts and their sources. In particular, the following were removed: a) non-coding SNPs; b) SNPs where polymorphisms have extremely low support (<10 reads in one sample); c) SNPs with more than two alleles, with the exception of loci known to be important for drug resistance, which were manually verified for artifacts; d) SNPs where coverage across samples is lower than the 25th percentile and higher than the 95th percentile of coverage in coding SNPs (these thresholds were determined from artifact analysis); e) SNPs located in regions of relatively low uniqueness (Manske et al., 2012); f) SNPs where heterozygosity levels were found to be inconsistent with the heterozygosity distribution at the SNP’s allele frequency; and g) SNPs where genotype could not be established in at least 70% of the samples. These analyses produced a final list of 935,601 high-quality SNPs in the 14 chromosomes of the nuclear genome, whose genotypes were used for analysis in this study.

All samples were genotyped at each high-quality SNP by a single allele, based on the number of reads observed for the two alleles at that position in the sample. At positions with fewer than 5 reads, the genotype was undetermined (no call was made). At all other positions, the sample was determined to be heterozygous if both alleles were each observed in more than 2 reads; otherwise, the sample was called as homozygous for the allele observed in the majority of reads. For the purposes of estimating allele frequencies and genetic distances, a within-sample allele frequency (fw) was also assigned to each valid call. For heterozygous calls, fw was estimated as ratio of non-reference read count to reference read count; homozygous calls were assigned f= 0 when called with the reference allele, and f= 1 when called with the non-reference allele.

The genotype of kelch13 was derived from read counts at non-synonymous SNP in the KPBD using a procedure described previously (Miotto et al., 2015)

Frequency estimation and clustering

Request a detailed protocol

For a given population P, we estimated the non-reference allele frequency (NRAF) at a given SNP as the mean of the within-sample allele frequency (fw) for all samples in P which have a valid genotype at that SNP. The minor allele frequency (MAF) at is the computed as min(NRAF, (1 – NRAF)).

To investigate the global population structure, we started by computing an NxN pairwise distance matrix, where N is the number of samples. Each cell of the matrix contained an estimate of genetic distance between the relevant pair of samples, obtained by summing the pairwise distance, estimated from within-sample allele frequency (fw), at each SNP in the 100 kbp window considered. When comparing a pair of samples sA and sB at a single SNP i where a genotype could be called in each sample, with within-sample allele frequencies fA and fB respectively, the distance dAB was estimated as dAB = fA (1- fB) + fB(1- fA). The genome-wide distance DAB between the two samples is then calculated as

DAB=αnABiwidAB

where nAB is the number of SNPs where both samples could be genotyped, wi is an LD weighting factor (see below) and α is a scaling constant, equal to 70% of the number of coding positions in the genome (since our genotyping covers approximately 70% of the coding genome). The exact value of α is uninfluential towards the analyses conducted in this study. The LD weighting factor, which corrects for the cumulative contribution of physically linked polymorphisms, was computed at each SNP i with MAF ≥ 0.1 in our sample set, by considering a window of m SNPs (j = 0.. m) centred at i. For each j, we computed the squared correlation coefficient r2ij between SNPs i and j. Ignoring positions j where where r2ij < 0.1, the weighting wi was computed by

wi=11+j rij2

A neighbour-joining tree was then produced using the nj implementation in the R ape package. Principal coordinate analysis (PCoA) was performed using the same pairwise distance matrices using the Classical Multidimensional Scaling (MDS) method (Gower, 1966) PCoA is a computationally efficient variant of principal component analysis (PCA) in which a pairwise distance matrix is used as input, rather than a table of genotypes. The matrix was supplied as input to the MDS algorithm, using the R language cmdscale implementation.

Conservation scoring and ancestral allele analysis

Request a detailed protocol

We analyzed homologous protein sequences of kelch13 genes for seven Plasmodium species for which high-quality sequence data were available: P. falciparum, P. reichenowi, P. vivax, P. knowlesi, P. yoelii, P. berghei, and P. chabaudi. The sequences were retrieved from the OrthoMCL cluster ORTHOMCL894 in GeneDB (http://www.genedb.org/), and a multiple alignment was obtained using ClustalW (Larkin et al., 2007) at default settings. In turn, we considered each pair alignment of P. falciparum with one of the remaining species, assigning a substitution score to each kelch13 amino acid position, derived from the CCF53P62 substitution matrix. Although this matrix was chosen due to its suitability for AT-rich codon biases (Brick and Pizzi, 2008), we found that use of the more commonly used BLOSUM62 matrix (Henikoff and Henikoff, 1992) did not have a significant effect on the results. Finally, each amino acid position was assigned a conservation score for the pair alignment, equal to the mean of the substitution scores in a 9-residue window centered at that position.

To reconstruct putative ancestral and derived alleles in the propeller domain, we catalogued all polymorphic positions in the multiple sequence alignment. We organized the seven species into three groups by similarity: Laverania (P. falciparum, P. reichenowi), primate Plasmodia (P. vivax, P. knowlesi) and rodent Plasmodia (P. yoelii, P. berghei, and P. chabaudi), and observed that at each position, only one of the groups presented an allele different from that in the remaining groups. This group-specific allele was labelled as a putative derived allele, and the alternative allele as ancestral. (see Table 5). Rodent species were found to carry the highest number of derived alleles, and therefore deemed to be good comparators for genome-wide conservation scoring. P. chabaudi was selected as a representative species in this group, and used for subsequent comparative analyses.

We estimated a gene conservation score for every P. falciparum gene for which a P. chabaudi orthologue sequence could be obtained from PlasmoDB (http://www.plasmodb.org/). The details of the method are described elsewhere (Gardner et al., 2011). Briefly, alignments of orthologous protein sequences were performed using ClustalW (Larkin et al., 2007) at default settings, and each amino acid position was assigned a CCF53P62 substitution score (see above). The gene conservation score assigned was equal to the mean substitution score for all amino acid positions in the gene.

Hydrophobicity analysis

Request a detailed protocol

Each amino acid position in the kelch13 was assigned a hydrophobicity score, estimated by computing the mean of the Kyte-Doolittle index in a 14-residue window centered at the position, using the protein sequence translated from the 3D7 reference sequence.

Chromosome painting

Request a detailed protocol

To reconstruct the probable origin of kelch13 flanking haplotypes in African mutants, we used chromosome painting (Lawson et al., 2012), a method that compares haplotypes in a sample to those in the remaining samples, and estimates probabilities that a genome fragment originates each population, by identifying individuals that share the same haplotype. For all African and SEA samples, we applied chromosome painting across the 250 kbp flanking regions on each side of the kelch13 gene. For each sample, haplotypes surrounding genome loci (chunks) were assigned posterior copying probabilities with respect to all remaining samples (unrestricted painting). We aggregated these probabilities according to the geographical origin of the donor samples, assigning to each chunk a probability that it originates from each of the populations. For each sample, we then estimated the expected fraction of chunks copied from each population.

In this analysis, we assumed a mutation rate per base per generation of 3.9-10 (Claessens et al., 2014) and a uniform recombination map. Since the two populations differ substantially in effective recombination rates (Mu et al., 2005), we assumed a conservative recombination rate of 30 kbp/cM. Effective population size was initially set to 10,000 and optimized by 10 iterations of the expectation-maximization procedure (Lawson et al., 2012). To account for the presence of heterozygous genotypes due to mixed infections, we modified the matrix of emission probabilities by introducing a novel parameter (ε, set to 10-8) to represent the probability of emitting a mixed call. We repeated the analysis varying this parameter set, to assess the effects of misspecification, and results were found to be very similar qualitatively (data not shown).

Data access and URLs

Request a detailed protocol

Illumina sequence reads have been submitted to the European Nucleotide Archive with study accessions ERP000190 (www.ebi.ac.uk/ena/data/view/ERP000190) and ERP000197 (www.ebi.ac.uk/ena/data/view/ERP000197). ENA accession numbers and metadata for the samples used in this paper can obtained via the MalariaGEN website, which also provides access to genotype calls on individual samples (www.malariagen.net/resource/16). Further details of all SNPs reported in this dataset including their genome coverage, mapping quality and allele frequencies in different populations, together with tools for querying the data, can be explored at www.malariagen.net/apps/pf.

Data availability

The following data sets were generated

References

    1. Bentley DR
    2. Balasubramanian S
    3. Swerdlow HP
    4. Smith GP
    5. Milton J
    6. Brown CG
    7. Hall KP
    8. Evers DJ
    9. Barnes CL
    10. Bignell HR
    11. Boutell JM
    12. Bryant J
    13. Carter RJ
    14. Keira Cheetham R
    15. Cox AJ
    16. Ellis DJ
    17. Flatbush MR
    18. Gormley NA
    19. Humphray SJ
    20. Irving LJ
    21. Karbelashvili MS
    22. Kirk SM
    23. Li H
    24. Liu X
    25. Maisinger KS
    26. Murray LJ
    27. Obradovic B
    28. Ost T
    29. Parkinson ML
    30. Pratt MR
    31. Rasolonjatovo IMJ
    32. Reed MT
    33. Rigatti R
    34. Rodighiero C
    35. Ross MT
    36. Sabot A
    37. Sankar SV
    38. Scally A
    39. Schroth GP
    40. Smith ME
    41. Smith VP
    42. Spiridou A
    43. Torrance PE
    44. Tzonev SS
    45. Vermaas EH
    46. Walter K
    47. Wu X
    48. Zhang L
    49. Alam MD
    50. Anastasi C
    51. Aniebo IC
    52. Bailey DMD
    53. Bancarz IR
    54. Banerjee S
    55. Barbour SG
    56. Baybayan PA
    57. Benoit VA
    58. Benson KF
    59. Bevis C
    60. Black PJ
    61. Boodhun A
    62. Brennan JS
    63. Bridgham JA
    64. Brown RC
    65. Brown AA
    66. Buermann DH
    67. Bundu AA
    68. Burrows JC
    69. Carter NP
    70. Castillo N
    71. Chiara E. Catenazzi M
    72. Chang S
    73. Neil Cooley R
    74. Crake NR
    75. Dada OO
    76. Diakoumakos KD
    77. Dominguez-Fernandez B
    78. Earnshaw DJ
    79. Egbujor UC
    80. Elmore DW
    81. Etchin SS
    82. Ewan MR
    83. Fedurco M
    84. Fraser LJ
    85. Fuentes Fajardo KV
    86. Scott Furey W
    87. George D
    88. Gietzen KJ
    89. Goddard CP
    90. Golda GS
    91. Granieri PA
    92. Green DE
    93. Gustafson DL
    94. Hansen NF
    95. Harnish K
    96. Haudenschild CD
    97. Heyer NI
    98. Hims MM
    99. Ho JT
    100. Horgan AM
    101. Hoschler K
    102. Hurwitz S
    103. Ivanov DV
    104. Johnson MQ
    105. James T
    106. Huw Jones TA
    107. Kang G-D
    108. Kerelska TH
    109. Kersey AD
    110. Khrebtukova I
    111. Kindwall AP
    112. Kingsbury Z
    113. Kokko-Gonzales PI
    114. Kumar A
    115. Laurent MA
    116. Lawley CT
    117. Lee SE
    118. Lee X
    119. Liao AK
    120. Loch JA
    121. Lok M
    122. Luo S
    123. Mammen RM
    124. Martin JW
    125. McCauley PG
    126. McNitt P
    127. Mehta P
    128. Moon KW
    129. Mullens JW
    130. Newington T
    131. Ning Z
    132. Ling Ng B
    133. Novo SM
    134. O’Neill MJ
    135. Osborne MA
    136. Osnowski A
    137. Ostadan O
    138. Paraschos LL
    139. Pickering L
    140. Pike AC
    141. Pike AC
    142. Chris Pinkard D
    143. Pliskin DP
    144. Podhasky J
    145. Quijano VJ
    146. Raczy C
    147. Rae VH
    148. Rawlings SR
    149. Chiva Rodriguez A
    150. Roe PM
    151. Rogers J
    152. Rogert Bacigalupo MC
    153. Romanov N
    154. Romieu A
    155. Roth RK
    156. Rourke NJ
    157. Ruediger ST
    158. Rusman E
    159. Sanches-Kuiper RM
    160. Schenker MR
    161. Seoane JM
    162. Shaw RJ
    163. Shiver MK
    164. Short SW
    165. Sizto NL
    166. Sluis JP
    167. Smith MA
    168. Ernest Sohna Sohna J
    169. Spence EJ
    170. Stevens K
    171. Sutton N
    172. Szajkowski L
    173. Tregidgo CL
    174. Turcatti G
    175. vandeVondele S
    176. Verhovsky Y
    177. Virk SM
    178. Wakelin S
    179. Walcott GC
    180. Wang J
    181. Worsley GJ
    182. Yan J
    183. Yau L
    184. Zuerlein M
    185. Rogers J
    186. Mullikin JC
    187. Hurles ME
    188. McCooke NJ
    189. West JS
    190. Oaks FL
    191. Lundberg PL
    192. Klenerman D
    193. Durbin R
    194. Smith AJ
    (2008) Accurate whole human genome sequencing using reversible terminator chemistry
    Nature 456:53–59.
    https://doi.org/10.1038/nature07517
    1. Escalante AA
    2. Ayala FJ
    (1995) Evolutionary origin of plasmodium and other apicomplexa based on rRNA genes
    Proceedings of the National Academy of Sciences of the United States of America 92:5793–5797.
    https://doi.org/10.1073/pnas.92.13.5793
    1. Henikoff S
    2. Henikoff JG
    (1992) Amino acid substitution matrices from protein blocks
    Proceedings of the National Academy of Sciences of the United States of America 89:10915–10919.
    https://doi.org/10.1073/pnas.89.22.10915
  1. Book
    1. World Health Organization
    (2014a)
    Update on Artemisinin Resistance - September 2014
    Geneva: World Health Organization.
  2. Book
    1. World Health Organization
    (2014b)
    World Malaria Report 2014
    Geneva: World Health Organization.

Article and author information

Author details

  1. MalariaGEN Plasmodium falciparum Community Project

    Contribution
    MGENPfCP, RA, OM, DPK, Conception and design, Analysis and interpretation of data, Drafting or revising the article, Approved the submitted manuscript; DMe, ED, SC, MK, MS, Developed and implemented sample processing and sequencing library preparation methods, Drafting or revising the article, Approved the submitted manuscript; AAN, CA, LAE, VA, TA, EA, SA, VB, AB, MFB, TB, PCB, DJC, AC, NPD, AD, CDo, AMD, CDr, PD, DFE, TGE, RMF, MAF, CIF, TTH, AH, MI, DI, PL, CL, JMa, KM, MMay, PM, VM, OAM, JMo, IM, MPK, PNN, FN, RN, AN, HO, AO, MO, J-BO, APPP, CP, RNP, SP, MR, PR, LR, DS, AS, PS, STH, T-NNT, VT, FV, JW, NJW, HY, GAA, SB, OB, KC, Carried out clinical studies and/or laboratory work to obtain parasite samples, Drafting or revising the article, Approved the submitted manuscript; CM, DJ, MMan, JS, Development and management of data production pipelines, Drafting or revising the article, Approved the submitted manuscript; CJW, JAG, IS, AM, RDP, PV, BJ, Developed analysis, software tools and methods, Drafting or revising the article, Approved the submitted manuscript; VJC, RG, DMu, CH, GM, KAR, BM, JCR, Contributed to study design and management, Drafting or revising the article, Approved the submitted manuscript.
    For correspondence
    1. dominic@sanger.ac.uk
    2. ra4@sanger.ac.uk
    3. olivo@tropmedres.ac
    Competing interests
    GM: Reviewing editor, eLife. The other authors declare that no competing interests exist.
    1. Roberto Amato, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
    2. Olivo Miotto, Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand
    3. Charles J Woodrow, Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand
    4. Jacob Almagro-Garcia, Centre for Genomics and Global Health, Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom
    5. Ipsita Sinha, Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand
    6. Susana Campino, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
    7. Daniel Mead, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
    8. Eleanor Drury, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
    9. Mihir Kekre, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
    10. Mandy Sanders, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
    11. Alfred Amambua-Ngwa, Medical Research Council Unit, Banjul, The Gambia
    12. Chanaki Amaratunga, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, United States
    13. Lucas Amenga-Etego, Navrongo Health Research Centre, Navrongo, Ghana
    14. Voahangy Andrianaranjaka, Malaria Research Unit, Institut Pasteur de Madagascar, Antananarivo, Madagascar
    15. Tobias Apinjoh, University of Buea, Buea, Cameroon
    16. Elizabeth Ashley, Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand
    17. Sarah Auburn, Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Australia
    18. Gordon A Awandare, West African Centre for Cell Biology of Infectious Pathogens, College of Basic and Applied Sciences, University of Ghana, Legon, Ghana
    19. Vito Baraka, National Institute for Medical Research, Tanga - Centre, Tanga, Tanzania
    20. Alyssa Barry, Division of Population Health and Immunity, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
    21. Maciej F Boni, University of Oxford, Ho Chi Minh City, Vietnam
    22. Steffen Borrmann, Kenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Kilifi, Kenya
    23. Teun Bousema, London School of Hygiene and Tropical Medicine, London, United Kingdom
    24. Oralee Branch, New York University School of Medicine, New York, United States
    25. Peter C Bull, Kenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Kilifi, Kenya
    26. Kesinee Chotivanich, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    27. David J Conway, Medical Research Council Unit, Banjul, The Gambia
    28. Alister Craig, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
    29. Nicholas P Day, Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand
    30. Abdoulaye Djimdé, Malaria Research and Training Centre, Faculty of Medicine, University of Bamako, Bamako, Mali
    31. Christiane Dolecek, Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam
    32. Arjen M Dondorp, Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand
    33. Chris Drakeley, London School of Hygiene and Tropical Medicine, London, United Kingdom
    34. Patrick Duffy, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, United States
    35. Diego F Echeverry, Department of Entomology, Purdue University, West Lafayette, United States
    36. Thomas G Egwang, Med Biotech Laboratories, Kampala, Uganda
    37. Rick M Fairhurst, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, United States
    38. Md. Abul Faiz, Malaria Research Group and Dev Care Foundation, Dhaka, Bangladesh
    39. Caterina I Fanello, Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand
    40. Tran Tinh Hien, Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam
    41. Abraham Hodgson, Navrongo Health Research Centre, Navrongo, Ghana
    42. Mallika Imwong, Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand
    43. Deus Ishengoma, National Institute for Medical Research, Tanga - Centre, Tanga, Tanzania
    44. Pharath Lim, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, United States
    45. Chanthap Lon, Department of Immunology and Medicine, US Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
    46. Jutta Marfurt, Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Australia
    47. Kevin Marsh, Kenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Kilifi, Kenya
    48. Mayfong Mayxay, Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Vientiane, Lao PDR
    49. Pascal Michon, Faculty of Medicine and Health Sciences, Divine Word University, Madang, Papua New Guinea
    50. Victor Mobegi, Medical Research Council Unit, Banjul, The Gambia
    51. Olugbenga A Mokuolu, Department of Paediatrics and Child Health, University of Ilorin, Ilorin, Nigeria
    52. Jacqui Montgomery, Department of Biology and Entomology, Pennsylvania State University, University Park, United States
    53. Ivo Mueller, Department of Medical Biology, University of Melbourne, Carlton, Australia
    54. Myat Phone Kyaw, Department of Medical Research Lower Myanmar, Ministry of Health, Yangon, Myanmar
    55. Paul N Newton, Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Vientiane, Lao PDR
    56. Francois Nosten, Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Mae Sot, Thailand
    57. Rintis Noviyanti, Eijkman Institute for Molecular Biology, Jakarta, Indonesia
    58. Alexis Nzila, Department of Biology, King Fahd University of Petroleum and Minerals, Dhahran, Saudi Arabia
    59. Harold Ocholla, Malawi Liverpool Wellcome Trust Clinical Research Programme, Malawi
    60. Abraham Oduro, Navrongo Health Research Centre, Navrongo, Ghana
    61. Marie Onyamboko, University of Kinshasa, Kinshasa, Democratic Republic of Congo
    62. Jean-Bosco Ouedraogo, Institut de Recherche en Sciences de la Sante, Direction Régionale de l'Ouést, Bobo-Dioulasso, Burkina Faso
    63. Aung Pyae P Phyo, Shoklo Malaria Research Unit, Bangkok, Thailand
    64. Christopher Plowe, Institute for Global Health, University of Maryland School of Medicine, Baltimore, United States
    65. Ric N Price, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
    66. Sasithon Pukrittayakamee, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    67. Milijaona Randrianarivelojosia, Malaria Research Unit, Institut Pasteur de Madagascar, Antananarivo, Madagascar
    68. Pascal Ringwald, Global Malaria Programme, World Health Organization, Geneva, Switzerland
    69. Lastenia Ruiz, Universidad Nacional de la Amazonia Peruana, Iquitos, Peru
    70. David Saunders, Department of Immunology and Medicine, US Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
    71. Alex Shayo, Department of Biotechnology and Bioinformatics, The University of Dodoma, Dodoma, Tanzania
    72. Peter Siba, Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea
    73. Shannon Takala-Harrison, Institute for Global Health, University of Maryland School of Medicine, Baltimore, United States
    74. Thuy-Nhien N Thanh, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
    75. Vandana Thathy, Kenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Kilifi, Kenya
    76. Federica Verra, London School of Hygiene and Tropical Medicine, London, United Kingdom
    77. Jason Wendler, Centre for Genomics and Global Health, Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom
    78. Nicholas J White, Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand
    79. Htut Ye, Department of Medical Research Lower Myanmar, Ministry of Health, Yangon, Myanmar
    80. Victoria J Cornelius, Centre for Genomics and Global Health, Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom
    81. Rachel Giacomantonio, Centre for Genomics and Global Health, Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom
    82. Dawn Muddyman, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
    83. Christa Henrichs, Centre for Genomics and Global Health, Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom
    84. Cinzia Malangone, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
    85. Dushyanth Jyothi, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
    86. Richard D Pearson, Centre for Genomics and Global Health, Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom
    87. Julian C Rayner, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
    88. Gilean McVean, Centre for Genomics and Global Health, Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom
    89. Kirk A Rockett, Centre for Genomics and Global Health, Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom
    90. Alistair Miles, Centre for Genomics and Global Health, Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom
    91. Paul Vauterin, Centre for Genomics and Global Health, Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom
    92. Ben Jeffery, Centre for Genomics and Global Health, Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom
    93. Magnus Manske, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
    94. Jim Stalker, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
    95. Bronwyn MacInnis, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
    96. Dominic P Kwiatkowski, Wellcome Trust Sanger Institute, Cambridge, United Kingdom

Funding

Wellcome Trust (WT Sanger Institute Core Funding, 98051)

  • Roberto Amato
  • Susana Campino
  • Daniel Mead
  • Eleanor Drury
  • Mihir Kekre
  • Mandy Sanders
  • Victoria J Cornelius
  • Rachel Giacomantonio
  • Dawn Muddyman
  • Cinzia Malangone
  • Dushyanth Jyothi
  • Richard D Pearson
  • Julian C Rayner
  • Kirk A Rockett
  • Alistair Miles
  • Heinrich M Manske
  • Jim Stalker
  • Bronwyn MacInnis
  • Dominic P Kwiatkowski

Wellcome Trust (WT Centre for Human Genetics Core Funding, 090532/Z/09/Z)

  • Roberto Amato
  • Jacob Almagro-Garcia
  • Victoria J Cornelius
  • Rachel Giacomantonio
  • Christa Henrichs
  • Richard D Pearson
  • Gilean McVean
  • Kirk A Rockett
  • Alistair Miles
  • Paul Vauterin
  • Ben Jeffery
  • Dominic P Kwiatkowski

Wellcome Trust (WT Stategic Award, 90770)

  • Roberto Amato
  • Olivo Miotto
  • Jacob Almagro-Garcia
  • Susana Campino
  • Daniel Mead
  • Eleanor Drury
  • Mihir Kekre
  • Lucas Amenga-Etego
  • Tobias Apinjoh
  • Abdoulaye Djimdé
  • Deus Ishengoma
  • Milijaona Randrianarivelojosia
  • Victoria J Cornelius
  • Rachel Giacomantonio
  • Dawn Muddyman
  • Christa Henrichs
  • Cinzia Malangone
  • Dushyanth Jyothi
  • Richard D Pearson
  • Kirk A Rockett
  • Alistair Miles
  • Paul Vauterin
  • Ben Jeffery
  • Heinrich M Manske
  • Jim Stalker
  • Bronwyn MacInnis
  • Dominic P Kwiatkowski

Medical Research Council (Centre for Genomics and Global Health, G0600718)

  • Roberto Amato
  • Olivo Miotto
  • Jacob Almagro-Garcia
  • Lucas Amenga-Etego
  • Tobias Apinjoh
  • Abdoulaye Djimdé
  • Deus Ishengoma
  • Victoria J Cornelius
  • Rachel Giacomantonio
  • Dawn Muddyman
  • Gilean McVean
  • Kirk A Rockett
  • Alistair Miles
  • Paul Vauterin
  • Ben Jeffery
  • Heinrich M Manske
  • Jim Stalker
  • Bronwyn MacInnis
  • Dominic P Kwiatkowski

Bill and Melinda Gates Foundation (Grant OPP1040463)

  • Roberto Amato
  • Olivo Miotto
  • Charles J Woodrow
  • Ipsita Sinha
  • Elizabeth Ashley
  • Nicholas P Day
  • Arjen M Dondorp
  • Mallika Imwong
  • Nicholas J White
  • Dominic P Kwiatkowski

Wellcome Trust (WT Mahidol University Oxford Tropical Medicine Research Programme, 0892375/H/09/Z)

  • Olivo Miotto
  • Charles J Woodrow
  • Ipsita Sinha
  • Elizabeth Ashley
  • Nicholas P Day
  • Arjen M Dondorp
  • Caterina I Fanello
  • Mayfong Mayxay
  • Paul N Newton
  • Francois Nosten
  • Nicholas J White

National Institute of Allergy and Infectious Diseases (Intramural Research Program)

  • Chanaki Amaratunga
  • Rick M Fairhurst
  • Pharath Lim

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

This study was conducted by the MalariaGEN Plasmodium falciparum Community Project, and was made possible by clinical parasite samples contributed by partner studies, whose investigators are represented in the author list. RA and OM contributed equally. In addition, the authors would like to thank the following individuals, who contributed to partner studies or to the MalariaGEN Resource Centre, making this study possible: James Abugri, Nicholas Amoako, Steven M Kiara, John Okombo, Rogelin Raherinjafy, Seheno Razanatsiorimalala, Hongying Jiang, Xin-zhuan Su. The sequencing, analysis, informatics and management of the Community Project are supported by the Wellcome Trust through Sanger Institute core funding (098051) and a Strategic Award (090770/Z/09/Z) and by the MRC Centre for Genomics and Global Health which is jointly funded by the Medical Research Council and the Department for International Development (DFID) (G0600718; M006212). AEB and IM acknowledge the Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS.

Version history

  1. Received: May 14, 2015
  2. Accepted: December 23, 2015
  3. Version of Record published: March 4, 2016 (version 1)
  4. Version of Record updated: March 8, 2016 (version 2)

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 7,005
    views
  • 1,476
    downloads
  • 216
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. MalariaGEN Plasmodium falciparum Community Project
(2016)
Genomic epidemiology of artemisinin resistant malaria
eLife 5:e08714.
https://doi.org/10.7554/eLife.08714

Share this article

https://doi.org/10.7554/eLife.08714

Further reading

    1. Epidemiology and Global Health
    2. Microbiology and Infectious Disease
    Edited by Prabhat Jha et al.
    Collection Updated

    eLife has published papers on many tropical diseases, including malaria, Ebola, leishmaniases, Dengue and African sleeping sickness.

    1. Epidemiology and Global Health
    Caroline Krag, Maria Saur Svane ... Tinne Laurberg
    Research Article

    Background:

    Comorbidity with type 2 diabetes (T2D) results in worsening of cancer-specific and overall prognosis in colorectal cancer (CRC) patients. The treatment of CRC per se may be diabetogenic. We assessed the impact of different types of surgical cancer resections and oncological treatment on risk of T2D development in CRC patients.

    Methods:

    We developed a population-based cohort study including all Danish CRC patients, who had undergone CRC surgery between 2001 and 2018. Using nationwide register data, we identified and followed patients from date of surgery and until new onset of T2D, death, or end of follow-up.

    Results:

    In total, 46,373 CRC patients were included and divided into six groups according to type of surgical resection: 10,566 Right-No-Chemo (23%), 4645 Right-Chemo (10%), 10,151 Left-No-Chemo (22%), 5257 Left-Chemo (11%), 9618 Rectal-No-Chemo (21%), and 6136 Rectal-Chemo (13%). During 245,466 person-years of follow-up, 2556 patients developed T2D. The incidence rate (IR) of T2D was highest in the Left-Chemo group 11.3 (95% CI: 10.4–12.2) per 1000 person-years and lowest in the Rectal-No-Chemo group 9.6 (95% CI: 8.8–10.4). Between-group unadjusted hazard ratio (HR) of developing T2D was similar and non-significant. In the adjusted analysis, Rectal-No-Chemo was associated with lower T2D risk (HR 0.86 [95% CI 0.75–0.98]) compared to Right-No-Chemo.

    For all six groups, an increased level of body mass index (BMI) resulted in a nearly twofold increased risk of developing T2D.

    Conclusions:

    This study suggests that postoperative T2D screening should be prioritised in CRC survivors with overweight/obesity regardless of type of CRC treatment applied.

    Funding:

    The Novo Nordisk Foundation (NNF17SA0031406); TrygFonden (101390; 20045; 125132).